Real-Time
Market Intelligence

TEL AVIV, Israel, Nov. 30, 2025 (GLOBE NEWSWIRE) -- Ellomay Capital Ltd. (NYSE American; TASE: ELLO) ("Ellomay" or the "Company"), a renewable energy and power generator and developer of renewable energy and power projects in Europe, Israel and USA, today reported the publication in Israel of financial statements as of and for the three and nine months ended September 30, 2025 of Dorad Energy Ltd. ("Dorad"), in which Ellomay currently indirectly holds approximately 16.9% through its indirect 50% ownership of Ellomay Luzon Energy Infrastructures Ltd. ("Ellomay Luzon Energy"). On November 30, 2025, Amos Luzon Entrepreneurship and Energy Group Ltd. (the "Luzon Group"), an Israeli public co

November 30, 2025 Philips pioneered detector-based spectral CT, which has been widely adopted in clinical routine exams across anatomies, supported by over 800 peer-reviewed publications [1]CE-marked, 510k pending Verida CT [2] integrates AI across the imaging chain, providing superb image quality while accelerating workflow and reducing dose [3, 4] Amsterdam, the Netherlands and Chicago, USA – At RSNA 2025, Royal Philips (NYSE:PHG, AEX: PHIA)), a global leader in health technology, today announced the launch of Verida, the world's first detector-based spectral CT fully powered by AI. This marks a transformative milestone in CT, with AI optimizing the entire imaging chain – lowering system

November 30, 2025 Major technology breakthrough combines advanced AI for clinical insights and accelerated workflow in new premium 3.0T MRI platform [1] Amsterdam, the Netherlands, and Chicago, USA – Royal Philips (NYSE:PHG, AEX: PHIA)), a global leader in health technology, today unveiled BlueSeal Horizon [1], an entirely new 3.0T MRI innovation platform that includes the industry's first helium-free 3.0T magnet at RSNA 2025. A pivotal advance in MRI innovation, helium-free [2] 3.0T is a major scientific achievement set to have significant impact for health providers and patients. 3.0T MRI systems are the most advanced MRI magnet technology in widespread use, providing high-resolution im

The company will showcase a wave of transformative innovations designed to address the most pressing challenges in healthcare, spanning the care journey across smart devices and drugs throughout disease states enabled by cloud and AI solutions. GE HealthCare has invested more than $3B in R&D since 2022, delivering an innovation renaissance across disease states to advance precision care. At this year's Radiological Society of North America's (RSNA) 2025 Annual Meeting, GE HealthCare (NASDAQ:GEHC) will showcase a wave of significant innovations grounded by its legacy and deep, global commitment to advancing precision care. For more than a century, GE HealthCare has stood at the intersec

Telsey Advisory Group reiterated coverage of Macy's with a rating of Market Perform and set a new price target of $22.00 from $17.00 previously

Citigroup resumed coverage of Liberty Broadband Corp. with a rating of Buy and set a new price target of $73.00

Analyst downgraded CNH Industrial from Neutral to Underweight and set a new price target of $10.00

Desjardins initiated coverage of Kinross Gold with a rating of Buy

4 - DoorDash, Inc. (0001792789) (Issuer)

4 - EAGLE CAPITAL GROWTH FUND, INC. (0000850027) (Issuer)

4 - Bausch Health Companies Inc. (0000885590) (Issuer)

4 - Goosehead Insurance, Inc. (0001726978) (Issuer)

4 - ASP Isotopes Inc. (0001921865) (Issuer)

3 - ASP Isotopes Inc. (0001921865) (Issuer)

4 - ASP Isotopes Inc. (0001921865) (Issuer)

3 - ASP Isotopes Inc. (0001921865) (Issuer)

SCHEDULE 13D/A - REPUBLIC AIRWAYS HOLDINGS INC. (0000810332) (Subject)

144 - Rackspace Technology, Inc. (0001810019) (Subject)

SCHEDULE 13D - Nabors Energy Transition Corp. II (0001975218) (Subject)

8-K - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Filer)

For Immediate Release: March 28, 2025 Today, the U.S. Food and Drug Administration approved Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A or hemophilia B, with or without factor VIII or IX inhibitors (neutralizing antibodies).“Today’s approval of Qfitlia is significant for patients wi

For Immediate Release: March 11, 2025 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:Today, the FDA published a General Correspondence Letter issued to Mid-Link Technology Testing Co., Ltd. The FDA is vigilant in ensuring data submitted to the FDA can be relied upon to assess the effectiveness, safety, or risk of a device. The FDA has noted an incr

For Immediate Release: February 28, 2025 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:On Thursday, the FDA approved Odactra to include use in individuals 5 through 11 years of age to treat house dust mite induced nasal inflammation (allergic rhinitis), with or without eye inflammation (conjunctivitis). Odactra is an allergen extract immunotherapy

For Immediate Release: February 21, 2025 Today, the U.S. Food and Drug Administration approved Ctexli (chenodiol) for the treatment of cerebrotendinous xanthomatosis (CTX) in adults. Ctexli is the first FDA-approved drug to treat CTX, a very rare lipid storage disease.“The FDA is dedicated to supporting new drug development for rare diseases including very rare metabolic diseases like cerebrotendinous xanthomato

CHENGDU, China, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Maase Inc. (NASDAQ:MAAS) ("MAAS" or the "Company") today announced the appointment of Mr. Jingkai Li as a director and the chairman of the board of directors (the "Board"), effective November 28, 2025. Mr. Li succeeds Ms. Hong Suong Nguyen, who has resigned from her positions as the chairperson and a director of the Board for personal reasons, effective on the same date. Mr. Li holds an executive master degree in business administration from Macau University of Science and Technology. His appointment reflects the Board's confidence in his profound management expertise, forward-looking investment vision, and extensive background in the gree

VANCOUVER, BC, Nov. 28, 2025 /PRNewswire/ - New Pacific Metals Corp. ("New Pacific" or the "Company") (TSX:NUAG) (NYSE:NEWP) today reported that all matters submitted for approval at New Pacific's annual meeting of shareholders ("AGM") held today as set out in the Company's Notice of Meeting and Management Information Circular, both dated October 24, 2025, were approved by the requisite majority of votes cast at  the AGM.  A total of 144,270,137 common shares, representing 78.53% of the votes attached to all outstanding shares as at the record date for the meeting, were represented at the AGM.  The details of the voting results for the election of directors are set out below: Votes For With

NEWPORT, R.I., Nov. 28, 2025 /PRNewswire/ -- Pangaea Logistics Solutions Ltd. ("Pangaea" or the "Company") (NASDAQ:PANL), a global provider of comprehensive maritime logistics solutions, today announced the appointment of Paul M. Leand, Jr. to the Company's Board of Directors as a Class III director, effective immediately. Mr. Leand has over two decades of experience advising companies and investors in the maritime shipping industry. He is the Managing Director and Chief Executive Officer of AMA Capital Partners, the only merchant banking partnership in the United States exclu

SARASOTA, Fla. and INDIANAPOLIS, Nov. 28, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (NASDAQ:IVF) ("INVO" or the "Company"), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies, today announced its intent to acquire Family Beginnings, P.C., a respected fertility clinic serving patients across Indiana and the broader Midwest. The planned acquisition marks INVO's second acquisition after its purchase of Wisconsin Fertility Institute in 2023 and reflects the Company's multi-pronged strategic initiative to build a nationwide network of fertility centers capable of reaching underserved markets an

TEL AVIV, Israel, Nov. 30, 2025 (GLOBE NEWSWIRE) -- Ellomay Capital Ltd. (NYSE American; TASE: ELLO) ("Ellomay" or the "Company"), a renewable energy and power generator and developer of renewable energy and power projects in Europe, Israel and USA, today reported the publication in Israel of financial statements as of and for the three and nine months ended September 30, 2025 of Dorad Energy Ltd. ("Dorad"), in which Ellomay currently indirectly holds approximately 16.9% through its indirect 50% ownership of Ellomay Luzon Energy Infrastructures Ltd. ("Ellomay Luzon Energy"). On November 30, 2025, Amos Luzon Entrepreneurship and Energy Group Ltd. (the "Luzon Group"), an Israeli public co

Saba Capital Income & Opportunities Fund (NYSE:BRW) (the "Fund"), a registered closed-end management investment company listed on the New York Stock Exchange, is notifying shareholders, prospective shareholders, and third parties of the sources of distributions pursuant to Section 19(a) of the Investment Company Act of 1940 (the "Investment Company Act"). IMPORTANT INFORMATION REGARDING MONTHLY DISTRIBUTION Distribution Notice. Pursuant to Section 19(a) of the Investment Company Act, the Fund is providing its shareholders with an estimate of the source of the Fund's monthly distribution as required by current securities laws. The Fund's estimated sources of the distribution to be paid on

Saba Capital Income & Opportunities Fund II (NYSE:SABA) (the "Fund"), a registered closed-end management investment company listed on the New York Stock Exchange, is notifying shareholders, prospective shareholders, and third parties of the sources of distributions pursuant to Section 19(a) of the Investment Company Act of 1940 (the "Investment Company Act"). IMPORTANT INFORMATION REGARDING MONTHLY DISTRIBUTION Distribution Notice. Pursuant to Section 19(a) of the Investment Company Act, the Fund is providing its shareholders with an estimate of the source of the Fund's monthly distribution as required by current securities laws. The Fund's estimated sources of the distribution to be pai

NEW YORK, Nov. 28, 2025 /PRNewswire/ -- Neuberger Berman Energy Infrastructure and Income Fund Inc. (NYSE:NML) (the "Fund") has announced a distribution declaration of $0.0584 per share of common stock. The distribution announced today is payable on December 31, 2025, has a record date of December 15, 2025, and has an ex-date of December 15, 2025. The Fund currently intends to make regular monthly cash distributions to holders of its common stock at a fixed rate per share, to be determined based on the projected net rate of return of the Fund's investments as well as other fac

SC 13D - CITIGROUP INC (0000831001) ()

SC 13D/A - KEYCORP /NEW/ (0000091576) ()

SC 13D/A - ALLIANCEBERNSTEIN HOLDING L.P. (0000825313) (Subject)

SC 13D/A - CVR ENERGY INC (0001376139) (Subject)

Recently, on July 4, 2024, a significant insider purchase was recorded at Allied Gaming & Entertainment Inc. as Large owner Choi Roy bought $456,750 worth of shares (360,000 units at $1.27), increasing direct ownership by 14% to 2,871,822 units (SEC Form 4). This purchase is notable for the size of the transaction and the percentage increase in direct ownership, indicating a strong belief in the company's future prospects. Insider purchases are generally viewed positively by investors as they signal confidence from those with intimate knowledge of the company's operations. Examining other recent insider transactions at Allied Gaming & Entertainment Inc., we notice a few patterns worth explo

Recently, on June 25, 2024, Director Romano Kelly A bought $100,051 worth of shares in Athira Pharma Inc. This transaction involved acquiring 42,400 units at $2.36 per share, resulting in a significant increase in direct ownership by 111% to 80,715 units. The purchase was disclosed in the SEC Form 4 filing. Insider buying is often considered a bullish signal as insiders may have insights into the company's future performance. It's essential to analyze this insider purchase in conjunction with previous insider transactions to identify any patterns or trends. Taking into account the information from the SEC filings, several other insiders at Athira Pharma Inc. have also been active in the sto

Recently, on June 26, 2024, Director Juda Scott bought $36,350 worth of shares (5,000 units at $7.27) (SEC Form 4) in INmune Bio Inc. This insider purchase is significant as it indicates confidence from someone within the company towards its future growth prospects. It's interesting to note that this purchase by Juda Scott follows a series of transactions by other insiders in the company. For example, Moss David J bought $149,993 worth of shares (18,028 units at $8.32) on April 24, 2024, increasing direct ownership by 1% to 1,268,179 units. This demonstrates a consistent trend of insider buying within the organization. Looking back at previous transactions, on May 16, 2024, several key ins

Monopar Therapeutics Inc. has recently seen notable insider activity, with Chief Operating Officer Cittadine Andrew purchasing $25,574 worth of shares on June 21st, 2024. This purchase, comprising 32,508 units at $0.79, increased Cittadine's direct ownership by 21% to 186,132 units as reported in the SEC Form 4. When analyzing this transaction alongside other recent insider activities within the company, interesting patterns and trends start to emerge. Looking back, Cittadine Andrew has been consistently adding to his position in Monopar Therapeutics Inc. over the past few months, showcasing a strong conviction in the company's future prospects. On May 31st, Cittadine Andrew made a substan